Organon & Co | OGN - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Celltrion KRW 119.22B 21.46B 2026-03
Cspc Pharmaceutical CNY 5.91B 512.77M 2025-12
Deva Holding AS TRY 1.35B 178.26M 2023-09
Dianthus Therapeutics USD 47M 22.83M 2026-03
Divis Laboratories Ltd INR 19.51B 660M 2026-06
Gilead Sciences USD 3.95B 19.57B 2026-06
Glaxosmithkline GBP 5.34B 3.83B 2026-03
Kangmei Pharma CNY 1.09B 304.02M 2026-03
Knight Therapeutics CAD 126.9M 8.29M 2025-12
Laboratorios Farma EUR 313.62M 17.98M 2023-12
Malin Corporation EUR 1.1M 400K 2024-12
Medical Developments International AUD 21.61M 11.59M 2025-12
Merck USD 15.77B 2.4B 2026-06
Neuren Pharmaceuticals AUD 25.23M 16.54M 2025-12
Novartis USD 9.29B 507M 2026-03
Organigram Holdings CAD 69.59M 14.08M 2026-03
Organon & Co USD 1.01B 103M 2026-06
Ovoca Bio EUR 173K 990K 2025-12
Pharma Mar EUR 51.01M 8.73M 2026-06
Qiagen NV USD 393.64M 17.95M 2026-06
Sartorius EUR 747.8M 9.4M 2026-06
Sino Biopharmaceutical CNY 12.39B 1.26B 2025-06
Tilray USD 237.52M 17.34M 2025-09
Zealand Pharma A/S 573M 202.97M 2026-03